Research · Sep 3, 2026
[INDV] Indivior Thesis 2026: A Specialty Pharma Bets Sublocade Growth Against Suboxone Generic Erosion
Indivior PLC (NASDAQ: INDV + LSE), headquartered in Slough, United Kingdom, is a specialty pharma company focused on opioid-use-disorder (OUD) + other addiction-treatment + behavioral-health indications. Spun off from Reckitt Benckiser (RB) in December 2014 as the RB-pharmaceutical-business containing Suboxone + Subutex + other OUD-related products. Suboxone (buprenorphine + naloxone), the dominant US opioid-agonist-treatment for moderate-to-severe OUD (FDA-approved 2002), reached ~$700M+ peak revenue in 2014-2017 era before 2018 patent-and-litigation-cleared generic-entry (Dr. Reddy's + Sandoz + Mylan/Viatris) eroded revenue to ~$250-350M today. Indivior launched Sublocade (buprenorphine extended-release monthly injection) in late-2017 as strategic pivot — Sublocade has scaled dramatically from $30M in 2018 to $700M+ by 2024 (~20x in 6 years) driven by opioid-epidemic-driven treatment demand (~10M+ US OUD patients with substantial unmet need + ~100K+ annual opioid-overdose deaths), monthly-injectable advantage vs daily-film adherence/retention, 2023 DATA-Waiver removal (Consolidated Appropriations Act eliminated X-Waiver requirement dramatically expanding prescriber-base from waivered-physicians to any DEA-registered practitioner), and expanded payer-coverage. DOJ + state-AG opioid-related litigation 2018-2022 alleged anti-competitive Suboxone-tablet-to-film switch + marketing practices; Indivior paid ~$600M+ cumulative settlements through 2020-2022 + former executive Shaun Thaxter pleaded guilty 2020. 2024 LSE-to-NASDAQ primary-listing migration for US-market focus + valuation potential. Under CEO Joe Ciaffoni (since 2024, succeeded longtime CEO Mark Crossley), FY2025 closes with selected various aggregate revenue ~$1.1-1.3B, adjusted EBITDA ~$0.30-0.45B, adjusted EPS ~$2.00-3.00, FCF ~$0.20-0.35B/yr, ~$0.4-0.6B net cash, and ~127M shares outstanding. The first deep-dive — the Sublocade extended-release-injection franchise for opioid-use-disorder — covers the strategic-and-growth-defining product at ~$0.65-0.80B+ revenue (~55-65% of total). Sublocade is monthly subcutaneous injection providing sustained-release buprenorphine at stable therapeutic levels for ~28-30 days post-administration, replacing daily-film with monthly clinician-administration — dramatically improves adherence/retention (~2-3x higher than daily-film). Growth drivers: opioid-epidemic demand (~10M+ US OUD patients, only ~10-15% receive MAT), monthly-injectable advantage vs daily-film, 2023 DATA-Waiver removal expanding prescriber-base, payer-coverage expansion (Medicaid + commercial + Medicare), and clinical-outcomes evidence. The Brixadi competitive challenge: Braeburn LLC's Brixadi approved May 2023 as competing weekly + monthly buprenorphine extended-release with weekly-dose-titration-flexibility option + different injection-formulation + pricing differentiation; competitive battle through 2025-2027 will determine continued Sublocade market-share. FY2026 catalyst is Sublocade growth durability, Brixadi competitive response, expanded coverage, and clinical-outcomes evidence-generation. The second deep-dive — Suboxone-film-decline + Perseris + pipeline + post-DOJ-settlement-era pivot — covers non-Sublocade portfolio. Suboxone film + tablet (~$250-350M revenue declining): legacy buprenorphine + naloxone sublingual franchise eroded from $700M+ peak by 2018 generic-entry; effectively in managed-decline. Perseris (long-acting injectable risperidone for schizophrenia, FDA-approved July 2018): struggling launch ~$50-80M revenue (vs original $200-300M+ expectations) crowded by Invega Sustenna/Trinza/Hafyera (Janssen), Abilify Maintena (Otsuka/Lundbeck), Aristada (Alkermes ALKS); Indivior exploring strategic-alternatives including divestiture. Opvee (intramuscular naloxone for opioid-overdose reversal) from Opiant Pharmaceuticals 2023 acquisition ~$145M; ~$10-30M revenue complementing Narcan (Emergent BioSolutions EBS). The post-DOJ-settlement-era pivot completed substantially with $600M+ settlements paid through 2020-2022; residual opioid-litigation continues but most major settlements completed. FY2026 catalyst is Suboxone decline-pacing, Perseris strategic-alternatives, Opvee growth, and further M&A or strategic-alternatives (Indivior periodically floated as strategic-acquisition target given Sublocade-franchise-value + post-Suboxone-portfolio-simplification + post-NASDAQ-migration). Comp set includes Alkermes (ALKS most-comparable CNS-addiction-specialty-pharma with Vivitrol + Aristada), Emergent BioSolutions (EBS Narcan), generic-buprenorphine (Dr. Reddy's, Viatris, Sandoz), specialty-pharma (Jazz JAZZ, Supernus SUPN, Axsome AXSM). Capital position is net-cash and share-repurchase-focused: ~$0.4-0.6B net cash, near-zero debt, FCF ~$0.20-0.35B/yr, capex ~$20-40M/yr modest, no dividend (UK-listed-pharma-atypical), modest opportunistic buybacks, ~127M shares broadly stable. At ~$12-22 per share, equity value ~$1.5-3.0B and EV ~$1.0-2.5B (net cash), ~3-8x EV/adj-EBITDA and ~5-10x EPS — substantial discount reflecting overhangs. Base case is ~15-25% total return; bull case is Brixadi-minimal-impact + Perseris-divestment + strategic-acquisition + 50-100%+ return; bear case is Brixadi share-loss + Suboxone acceleration + de-rating.